Larkspur Health Acquisition Corp.
Status: Deal Closed
U=S+(3/4)W
W=S@11.5
| IPO Proceeds, $M | $77.67M |
|---|---|
| IPO Date | Dec 21, 2021 |
| Left Lead | A.G.P |
| IPO Cash in Trust | 101.0% |
| SPAC Tenor | 12 + (2*3) |
| IPO Sector |
Healthcare
Biotechnology in the US |
| IPO Geography | US/Canada |
| Target Company | ZyVersa Therapeutics |
| Deal Announced | Jul 21, 2022 |
| Deal Size, $M | $108.92M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings | www.sec.gov |
| Approval Vote | Dec 8, 2022 |
| Amendment Vote | TBD |
| Closing Date | Dec 12, 2022 |
Formerly LSPR
ZVSA
ZVSAW
| Price | $1.11 $0.00 |
|---|---|
| Last closing price | $1.23 |
| H/L, today | $1.10 / $1.19 |
| H/L, 52-week | $0.07 / $24.29 |
| Volume, today | 2,681,912 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Larkspur Health Acquisition Corp.:
- Structure and cap table
- 5 directors & officers
- 28 filings and events
- 3 underwriters
- 2 deal advisors
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Daniel J. O'Connor | 57 | Chairman, CFO and Director |
| David S. Briones | 45 | CFO and Treasurer and Director |
| Raj Mehra, Ph.D., J.D. | 60 | Director |
| Gregory Skalicky | 49 | Director |
| Christopher Twitty, Ph.D. | 49 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| A.G.P | BR | 5,066,668 | units |
| Brookline Capital Markets | 766,666 | ||
| The Benchmark Company | 1,666,666 | ||
| 7,500,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| BCMA | 4.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.